Mizuho lowered the firm’s price target on LivePerson to $7 from $12 and keeps a Neutral rating on the shares. The company reported Q4 revenue below consensus, partly due to suspension of Medicare reimbursements for Wild Health, and negative adjusted EBITDA, driven by cash bonus payments for employees, the analyst tells investors in a research note. The firm expects 2023 will be a difficult transition year for LivePerson.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LPSN:
Click Here to Read the Full Original Article at TipRanks Financial Blog…